SLXN

Silexion Therapeutics Corp (SLXN) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Silexion Therapeutics Corp is a clinical-stage biotechnology company focused on developing RNAi therapeutics to silence the KRAS oncogene, primarily for pancreatic cancer. The company operates as a single segment and is currently in a development stage with no product revenue. Following a business combination in August 2024, the company is listed on the Nasdaq Capital Market.

Key Financial Metrics

Note: All figures in millions unless otherwise stated. The company reported a loss per share of $8.21 for the six months and $4.32 for the quarter.

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses increased by 49.3% to $3.93 million for the six months ended June 30, 2025, compared to $2.64 million in the prior year period. This was driven primarily by a 155.6% increase in General and Administrative (G&A) expenses to $2.33 million, attributed to higher payroll and professional service costs associated with public company operations.
• Research & Development (R&D): R&D expenses decreased slightly by 5.9% to $1.61 million for the six-month period, due to a reduction in subcontractor costs, partially offset by increased payroll expenses.
• Net Loss: Net loss increased by 44.8% to $4.24 million for the six-month period compared to $2.91 million in the prior year.
• Financing Activity: The company raised significant capital in the first half of 2025, including a $5.0 million public offering and approximately $3.3 million from an induced warrant exercise transaction in January 2025.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern: Management has concluded there is substantial doubt about the company's ability to continue as a going concern for at least 12 months from the filing date. Current cash reserves are estimated to fund operations only into the first quarter of 2026.
• Nasdaq Compliance: The company received a favorable decision from a Nasdaq hearings panel to remain listed on the Nasdaq Capital Market, subject to a compliance plan. The company must demonstrate shareholders' equity of at least $2.5 million by September 19, 2025. To address a bid price deficiency, the company effected a 1-for-15 reverse share split on July 28, 2025.
• Capital Requirements: The company expects to incur significant losses as it advances its lead product candidate, SIL204, through pre-clinical and clinical trials. Additional funding is required via equity offerings, the ELOC (Equity Line of Credit), or other financing.
• Subsequent Events: In August 2025, the company completed another induced warrant exercise transaction raising approximately $1.8 million. Shareholders are scheduled to vote on an increase in authorized share capital on August 12, 2025.

Investor Verification Checklist

• Liquidity Runway: Verify the company's ability to raise the necessary capital to meet the $2.5 million shareholders' equity requirement by September 19, 2025, to avoid delisting.
• Dilution Risk: Assess the impact of recent and planned equity issuances (public offerings, warrant inducements, ELOC) on existing shareholder ownership.
• Going Concern Status: Review the "Going Concern" note in the financial statements and the auditor's report regarding the uncertainty of future operations.
• Reverse Split Impact: Confirm the trading status and share price following the 1-for-15 reverse share split effective July 29, 2025.
• Debt Obligations: Monitor the status of the A&R Sponsor Promissory Note ($3.43 million) and other related party liabilities.